Sandler Capital Management Trims Holdings in Repligen Corporation $RGEN

Key Points

• Sandler Capital Management reduced its stake in Repligen Corporation by 31.5% in the first quarter, selling 8,004 shares and now holding 17,389 shares valued at approximately $2.2 million.
• Repligen's recent quarterly earnings report showed a net revenue of $182.37 million, exceeding analyst expectations, but the company's earnings per share (EPS) fell short of estimates at $0.37.
• Repligen's stock has been recently rated with an average of "Moderate Buy" by analysts, with a consensus price target of approximately $169.55.

Sandler Capital Management lessened its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 31.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,389 shares of the biotechnology company's stock after selling 8,004 shares during the period. Sandler Capital Management's holdings in Repligen were worth $2,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in RGEN. Alliancebernstein L.P. lifted its stake in Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock worth $130,317,000 after acquiring an additional 13,284 shares during the period. AQR Capital Management LLC bought a new stake in shares of Repligen in the 1st quarter valued at about $262,000. Advisors Asset Management Inc. lifted its position in shares of Repligen by 3.5% in the 1st quarter. Advisors Asset Management Inc. now owns 11,138 shares of the biotechnology company's stock worth $1,417,000 after purchasing an additional 378 shares during the period. Alyeska Investment Group L.P. boosted its stake in shares of Repligen by 24.0% during the first quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company's stock valued at $58,561,000 after purchasing an additional 89,057 shares in the last quarter. Finally, First Light Asset Management LLC increased its holdings in Repligen by 6.5% during the first quarter. First Light Asset Management LLC now owns 87,850 shares of the biotechnology company's stock valued at $11,178,000 after buying an additional 5,395 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Shares of RGEN stock traded up $1.54 during mid-day trading on Wednesday, hitting $120.23. 986,487 shares of the stock were exchanged, compared to its average volume of 663,220. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The firm has a fifty day moving average of $121.16 and a 200 day moving average of $128.66. The company has a market cap of $6.76 billion, a PE ratio of -480.90, a price-to-earnings-growth ratio of 2.18 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same period in the previous year, the firm posted $0.40 EPS. Repligen's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on RGEN. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Wednesday, September 3rd. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $169.55.

Insider Activity at Repligen

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.